Silevertinib

BDTX-1535 (EGFR-IN-76) is an orally available, blood-brain permeable, selective EGFR inhibitor with anti-tumor activity. BDTX-1535 is indicated in a variety of models including non-small cell lung cancer, glioblastoma patient-derived tumors, and intracranial tumors[1][2][3].

Product Specifications

CAS Number

[2607829-38-7]

Product Name Alternative

BDTX-1535; EGFR-IN-76

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bdtx-1535.html

Purity

99.47

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(/C=C/CN1CCOCC1)NC2=CC3=C(N=CN=C3NC4=C(C(Cl)=CC=C4)F)C=C2C#C[C@]56[C@](CN(C6)C)([H])C5

Molecular Formula

C30H30ClFN6O2

Molecular Weight

561.05

Precautions

H302, H315, H319

References & Citations

[1]O'Connor M, et al. Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM[J]. Cancer Research, 2023, 83 (7_Supplement) : 3396-3396.|[2]Lucas M, et al. BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC[J]. European Journal of Cancer, 2022, 174: S22.|[3]Lucas MC, et al. Preparation of alkynyl quinazoline compounds as anticancer agents. World Intellectual Property Organization, WO2021030711 A1. 2021-02-18.